By reducing and normalizing key inflammatory mediators such as CCL26 and TSLP, while preserving essential antiviral defense mechanisms, IL-4Rα blockade offers a balanced approach to managing asthma symptoms and preventing exacerbations. This evidence concerns the gene TSLP and asthma.